Quantum Genomics Announces Reshuffle of its Board of Directors and Restructuring of its Workforce to Focus on New Projects
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs that act directly on the brain, announces a reshuffle of its Board of Directors, a restructuring of its workforce and provides a new update on its strategic discussions.
Reshuffle of the Board of Directors
Meeting on February 21, 2023, the Board of Directors of Quantum Genomics, composed of Lionel Ségard (Chairman), Jean-Philippe Milon (Chief Executive Officer), Francois Durvye (Chief Executive Officer of Otium Capital), François Pelen (Independent Director) and Carole Wassermann (Independent Director), took note of the resignation from his position as Director of Frédéric Duchesne (Independent Director), whose past experience in the pharmaceutical industry was to be used for the marketing phase of firibastat in cardiology.
The Board of Directors then decided to dismiss Lionel Sgard, President and Founder of Quantum Genomics.
In replacement of the dismissed Chairman, the Board of Directors proposed and decided on the appointment of Jean-Philippe Milon (Chief Executive Officer of Quantum Genomics) as Chairman of the Board of Directors, in addition to his mandate as Chief Executive Officer. This proposal was accepted and acted upon by the Board of Directors. Jean-Philippe Milon now holds the position of Chairman and CEO of Quantum Genomics.
The Company also specifies that the office of Chairman of the Board of Directors will not be subject to any compensation.
Evolution of the organization chart
Following the negative results of the phase III FRESH study in resistant hypertension and the decision to prematurely stop the second phase III REFRESH study in this same indication and more broadly the development of firibastat in cardiology, Quantum Genomics implemented a staff restructuring plan involving the disappearance of functions related to the marketing process for firibastat in cardiology.
“I would like to warmly thank all the employees of Quantum Genomics who have worked tirelessly to make firibastat a success as well as those who are now maintaining their efforts to allow the Company to be part of a new corporate project. commented Jean-Philippe Milon, Chairman and CEO of Quantum Genomics.
Ongoing discussions with Biotech / Medtech companies
Quantum Genomics has initiated discussions with several Biotech and Medtech companies, listed and unlisted, and is studying all the opportunities and methods of possible mergers to build a new business project.
After analyzing more than twenty files, the Company selected two projects, a Biotech company and a Medtech company, both unlisted, for which advanced discussions with the management teams and “due diligence” procedures » operational are in progress.
These strategic discussions are conducted in close collaboration with Otium Capital, the Company’s leading shareholder.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of drugs based on the mechanism of inhibition of brain Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it relies on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr. Catherine Llorens-Cortès at France secondary school.
Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).
More information on www.quantum-genomics.com, our Twitter and Linkedin accounts
contacts
|
Quantum Genomics | |
|
Communication building (EUROPE) | |
Financial communication and media | |
|
LifeSci (USA) | |
Mike Tattory |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
mGqblpRrZ2yXyXGaZciZb2SXmW1llJScaGiYxZabaZ6dmZ5lm29jmpbLZnBpm2tv
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/78669-cp-22-fevrier-2023-version-francaise.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com